trans-2-(iodomethyl)cyclohexan-1-ol | 62872-54-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trans-2-(iodomethyl)cyclohexan-1-ol
• 英文别名: trans-2-iodomethylcyclohexanol；trans-Iodomethyl-2-cyclohexanol；trans-2-Iodmethylcyclohexanol；(1R,2R)-2-(iodomethyl)cyclohexan-1-ol
• CAS: 62872-54-2；63453-98-5
• 化学式: C₇H₁₃IO
• 分子量: 240.084
• InChiKey: BOUDTEYAGBITKT-NKWVEPMBSA-N

物化性质

• 沸点：
  271.9±13.0 °C(Predicted)
• 密度：
  1.674±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  trans-2-(iodomethyl)cyclohexan-1-ol 、 对甲苯磺酰氯 在 吡啶 作用下， 生成 trans-2-Iodmethyl-1-tosyloxycyclohexan
  参考文献：
  名称：

  消除反应1,3：顺丁基反式锂磺胺基乙基-2-甲苯磺酰氧基-1环己烷（ènes）的顺式和反式。摩西主义

  摘要：

  的反应顺式和失败者2-碘甲基-1- tosyloxycyclohexanes和4 -烯用nBuLi进行了研究并发现是立体有择的，产品分别为双环（4.1.0）己烷（烯）顺式和亚甲基环己烷（烯）。该反应与环状1,2-卤代醇的碱性脱氢卤化反应相似。提出了反应途径。

  DOI：

  10.1016/0040-4020(76)80144-5
• 作为产物：
  描述：

  trans-2-(p-toluenesulfonyloxymethyl)-cyclohexanol 在 sodium iodide 作用下， 以 丙酮 为溶剂， 生成 trans-2-(iodomethyl)cyclohexan-1-ol
  参考文献：
  名称：

  消除反应1,3：顺丁基反式锂磺胺基乙基-2-甲苯磺酰氧基-1环己烷（ènes）的顺式和反式。摩西主义

  摘要：

  的反应顺式和失败者2-碘甲基-1- tosyloxycyclohexanes和4 -烯用nBuLi进行了研究并发现是立体有择的，产品分别为双环（4.1.0）己烷（烯）顺式和亚甲基环己烷（烯）。该反应与环状1,2-卤代醇的碱性脱氢卤化反应相似。提出了反应途径。

  DOI：

  10.1016/0040-4020(76)80144-5

文献信息

• Reactions of silver(<scp>I</scp>) acetate–iodine and thallium(<scp>I</scp>) acetate–iodine with substituted cyclopropanes
  作者：Peter H. Atkinson、Richard C. Cambie、Graham Dixon、Wendy I. Noall、Peter S. Rutledge、Paul D. Woodgate

  DOI：10.1039/p19770000230

  日期：——

  Treatment of phenylcyclopropane with silver(I) acetate–iodine or thallium(I) acetate–iodine gives, as the major products, 1,3-disubstituted phenylpropanes resulting from cyclopropane ring opening, and in some cases, from solvolysis of intermediate iodo-acetates. Similar products are given with silver(I) trifluoroacetate–iodine but in this case aromatic iodination also occurs. Treatment of norcarane

  用乙酸碘化银（I）或乙酸碘化th（I）处理苯基环丙烷，作为主要产物，是由环丙烷开环以及某些情况下由中间碘代乙酸盐的溶剂化产生的1,3-二取代苯基丙烷。三氟乙酸银（I）-碘也可提供类似的产品，但在这种情况下也会发生芳族碘化。用相同的试剂处理正二十烷也会导致开环，但此处的副产物是通过消除和随后添加而产生的。两种底物对烯烃对每种试剂的反应性均不如烯烃。讨论了反应机理。据报道其他涉及亲电碘与苯基环丙烷和正戊烷的试剂系统的作用。
• Benzolactam compounds as protein kinase inhibitors
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US10457669B2

  公开（公告）日：2019-10-29

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

  本发明提供了一种式 (0) 的化合物： 或其药学上可接受的盐、N-氧化物或同系物；其中 n 是 1 或 2 X 是 CH 或 N Y 选自 CH 和 C-F Z 选自 C-Rz 和 N； R1 选自 -(Alk1)t-Cyc1；其中 t 为 0 或 1； 任选取代的 C1-6 无环烃基团 R2 选自氢、卤素和任选被一个或多个氟原子取代的 C1-3 烃基； R3 是氢或基团 L1-R7； R4 选自氢、甲氧基和任选被取代的 C1-3 烷基；以及 R4a 选自氢和 C1-3 烷基； 其中 Rz、Alk1、Cyc1、L1 和 R7 在本文中定义； 只要该化合物不是 6-苄基-3-2-[(2-甲基嘧啶-4-基)氨基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮和 3-2-[(2-甲基嘧啶-4-基)氨基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮及其盐和它们的同系物。 这些化合物是 ERK1/2 激酶的抑制剂，可用于治疗 ERK1/2 介导的疾病。因此，这些化合物可用于治疗，特别是治疗癌症。
• Phosphonomethylation of cyclohexene oxides
  作者：Jean Luc Montchamp、Marie E. Migaud、John W. Frost

  DOI：10.1021/jo00079a010

  日期：1993.12

  The tradeoff between synthetic directness and regioselectivity during oxirane ring opening is examined for two strategies used to phosphonomethylate cyclohexene oxide and substituted cyclohexene oxides derived from quinic acid and myo-inositol. Direct phosphonomethylation of the cyclohexene oxides utilizes diisopropyl lithiomethanephosphonate ((C3H7O)2P(O)CH2Li) in combination with boron trifluoride. Another more indirect route to phosphonomethylation begins with reaction of the cyclohexene oxides with (lithiomethyl)dimesitylborane (Mes2BCH2Li). In both reactions, boron plays a key role as either a Lewis acid during opening of the oxirane (diisopropyl lithiomethane-phosphonate/boron trifluoride) or as a stabilizer of an adjacent carbanion in the attacking nucleophile [(lithiomethyl)dimesitylborane]. Regioselectivities for oxirane ring opening using diisopropyl lithiomethanephosphonate/boron trifluoride can be quite modest. By contrast, oxirane ring openings employing (lithiomethyl)dimesitylborane are uniform in the high degree of regioselectivity which is achieved. Factors which might influence the observed regioselectivities during nucleophilic attack on the cyclohexene oxides are also discussed.
• Cambie, Richard C.; Dixon, Graham; Rutledge, Peter S., Journal of the Chemical Society. Perkin transactions I, 1982, p. 961 - 966
  作者：Cambie, Richard C.、Dixon, Graham、Rutledge, Peter S.、Woodgate, Paul D.

  DOI：——

  日期：——
• BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20190047990A1

  公开（公告）日：2019-02-14

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—R z and N; R 1 is selected from: -(Alk 1 ) t -Cyc 1 ; wherein t is 0 or 1; Optionally substituted C 1-6 acyclic hydrocarbon groups R 2 is selected from hydrogen; halogen; and C 1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R 3 is hydrogen or a group L 1 -R 7 ; R 4 is selected from hydrogen; methoxy; and optionally substituted C 1-3 alkyl; and R 4a is selected from hydrogen and a C 1-3 alkyl group; wherein R z , Alk 1 , Cyc 1 , L 1 and R 7 are defined herein; provided that the compound is other than 6-benzyl-3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.